Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 8, 2017, details the results of Atara Biotherapeutics, Inc.'s annual meeting of stockholders held on that date. The filing addresses corporate governance matters submitted to a vote by security holders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the outcomes of stockholder votes and does not contain financial performance data.
Material Changes
No material financial changes are reported in this document. The primary events are the successful election of directors and the ratification of the independent auditor.
Outlook, Risks, and Management Commentary
Management commentary is limited to the reporting of vote tallies. No specific guidance, outlook, risks, or contingencies are disclosed in this filing. For detailed descriptions of the matters voted upon, the filing references the definitive proxy statement filed on April 25, 2017.
Key Facts for Investors
- Director Election: Stockholders elected Isaac Ciechanover, M.D., and Carol Gallagher, Pharm.D., to serve until the 2020 annual meeting.
- Auditor Ratification: Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017.
- Voting Results:
- Isaac Ciechanover: 23,823,217 votes for; 469,559 withheld; 1,967,538 broker non-votes.
- Carol Gallagher: 23,364,751 votes for; 928,025 withheld; 1,967,538 broker non-votes.
- Auditor Ratification: 26,259,274 votes for; 1,040 against; 0 abstentions.
- Emerging Growth Company Status: The registrant is identified as an emerging growth company.